Company news

Filter by year

Oncopeptides launches Spanish website

May 2, 2024
As part of the company´s ongoing efforts to increase our visibility in Spain and strengthen relationships with the Spanish community, Oncopeptides recently launched
Read more

Clarification regarding recent decision from NICE

April 25, 2024
Oncopeptides has, as reported in the media, decided to not pursue an appraisal with the National Institute for Health And Care Excellence (NICE) in the United Kingdom at this time. On Thursday morning, the company clarified this decision in an interview with the news agency Direkt.
Read more

Oncopeptides secures national reimbursement for Pepaxti in Spain

April 15, 2024
Oncopeptides AB announces the approval of price and reimbursement allowing Oncopeptides to start commercializing its flagship drug Pepaxti in Spain as early as in 2024. Preparations ongoing with full launch expected to commence after summer.
Read more

Oncopeptalks on Q1 sales and MENA partnership

April 4, 2024
Sofia Heigis, CEO discusses recent news in the latest edition of Oncopeptalks.
Read more

Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa

March 27, 2024
Oncopeptides AB and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”).
Read more

Oncopeptides receives decision from the U.S. Food and Drug Administration confirming withdrawal of Pepaxto from the U.S. market

February 23, 2024
Oncopeptides AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has made a decision regarding the withdrawal of Pepaxto, which Oncopeptides had appealed.
Read more

Oncopeptides receives positive recommendation for Pepaxti by Spanish Pricing Authority

February 23, 2024
Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the Spanish Drug Pricing Authority (CIPM) has published a positive recommendation for the pricing of melflufen, branded in Europe as Pepaxti.
Read more

Oncopeptides ensures five years extended market exclusivity for Pepaxti in Europe

February 15, 2024
Oncopeptides AB today announces that it will receive an extension of a key patent ensuring market exclusivity for melflufen, marketed in Europe as Pepaxti, in Europe until 2037, an extension of five years.
Read more

Oncopeptides ranked among the top 10 companies in the Nordic Business Diversity Index 2024

February 9, 2024
February 9, 2024 - Oncopeptides was recently ranked in the top 10 in the Nordic Business Diversity Index’s Sweden small-cap category.
Read more

No update from the FDA regarding Oncopeptides’ appeal

January 8, 2024
January 8, 2024 - Oncopeptides has not yet received any notification from the US Food and Drug Administration (FDA) regarding the company's appeal of the authority's request to withdraw Pepaxto's approval in the US. Oncopeptides has not received any time indication for when an announcement may come. 
Read more

Update on the Type II application process

December 15, 2023
December 15, 2023 - Oncopeptides announces that the European Commission has decided to formally approve the company’s application to the European Medicines Agency (EMA) for an extended indication for Pepaxti into earlier lines. The previously communicated decision by Oncopeptides to opt out of the process to extend the indication remains.
Read more

Oncopeptides Chief Financial Officer Henrik Bergentoft takes office today

November 13, 2023
November 13, 2023 - Henrik brings 20+ years of experience from leading finance roles at both medical and non-medical, publicly listed organizations.
Read more

German price of Pepaxti published

October 30, 2023
Oncopeptides recently successfully agreed on a reimbursed price for Pepaxti in Germany that in the company´s view reflects the innovation of the drug and is in line with the company´s financial projections.
Read more

Update on Oncopeptides’ appeal of U.S. withdrawal

October 3, 2023
On Monday, October 2, Oncopeptides participated in a joint meeting with the Center for Drug Evaluation and Research’s (CDER’s) hosted by Dr. Peter Marks. The meeting presented an opportunity for both parties to present their view on the issue. The materials used, including meeting notes, will be posted in the public docket in the future, we don´t have information on when.
Read more

Oncopeptides opts to abandon Type II variation process for Pepaxti to optimize patient and shareholder value

September 28, 2023
The decision does not impact the company´s financial projections or the estimated market potential of Pepaxti negatively.
Read more

Oncopeptides announces successful price negotiations for Pepaxti in Germany

September 26, 2023
Oncopeptides announces that following negotiations between Oncopeptides and the German Federal Joint Committee National Association of Statutory Health Insurance Funds (GKV-Spitzenverband), a reimbursed price for Pepaxti has been agreed on in Germany. The negotiated reimbursed price in Germany, which will also guide negotiations in other European markets, is reflective of the innovation Pepaxti brings to the market, and in line with the company´s financial projections.
Read more

Oncopeptides appoints David Augustsson as Director of Corporate Affairs

May 31, 2023
Read more

The founders of Oncopeptides awarded

August 26, 2021
We are very proud and happy to share that Oncopeptide's founders, Professor Rolf Larsson, Professor Peter Nygren and Associate Professor Joachim Gullbo, were today awarded the Uppsala University Award Hjärnäpplet (Brain apple) for their successful work to improving drug treatment in cancer.
Read more